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Abstract
Summary This consensus article reviews the diagnosis and
treatment of osteoporosis in geriatric populations. Specifical-
ly, it reviews the risk assessment and intervention thresholds,
the impact of nutritional deficiencies, fall prevention strate-
gies, pharmacological treatments and their safety consider-
ations, the risks of sub-optimal treatment adherence and strat-
egies for its improvement.
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Introduction This consensus article reviews the therapeutic
strategies and management options for the treatment of oste-
oporosis of the oldest old. This vulnerable segment (persons
over 80 years of age) stands to gain substantially from effec-
tive anti-osteoporosis treatment, but the under-prescription of
these treatments is frequent.
Methods This report is the result of an ESCEO (European
Society for Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis) expert working group, which explores
some of the reasons for this and presents the arguments to
counter these beliefs. The risk assessment of older individuals
is briefly reviewed along with the differences between some
intervention guidelines. The current evidence on the impact of
nutritional deficiencies (i.e. calcium, protein and vitamin D) is
presented, as are strategies to prevent falls. One possible
reason for the under-prescription of pharmacological treat-
ments for osteoporosis in the oldest old is the perception that
anti-fracture efficacy requires long-term treatment. However,
a review of the data shows convincing anti-fracture efficacy
already by 12 months.
Results The safety profiles of these pharmacological agents
are generally satisfactory in this patient segment provided a
few precautions are followed.
Conclusion These patients should be considered for particular
consultation/follow-up procedures in the effort to con-
vince on the benefits of treatment and to allay fears of
adverse drug reactions, since poor adherence is a major
problem for the success of a strategy for osteoporosis
and limits cost-effectiveness.
Keywords Ageing . Drug adherence . Fracture risk . Frailty .
Malnutrition .Muscle weakness . Osteoporosis . Review
Introduction
In view of the progressive ageing of most of the world’s
populations, it can be expected that the incidence of age-
related conditions will grow and therefore the treatment and
management of these individuals will gain increasing priority.
Osteoporosis and frailty, which together greatly increase
the risk of fracture, are of particular concern. Hip fractures are
the most serious osteoporotic fractures, with high risk of
mortality. A large proportion of patients (more than 50 %)
admitted to hospital with hip fracture are over 80 years old [1].
The survivors have a high risk of sustaining another major
fracture and face deterioration in their quality of life and risk
of dependency. Whilst the prevalence of osteoporotic facture
is higher in women than men, it is clear that the risk in men is
not negligible and ageing men have a greater risk of mortality
and morbidity following hip fracture than do women [2].
With a focus on osteoporosis, this review builds on previ-
ous review [3] to examine new evidence and guidance for
diagnosis and treatment options for the oldest old (80 years
and older). The efficacy and safety information on the oldest
group is sparse since this age group is rarely included in
randomised controlled trials (RCT). But this is beginning to
change and more subgroup analyses in older patients are also
being published. Of particular interest are new data
concerning nutritional supplementation as well as new effica-
cy studies of pharmacological agents. Although a number of
effective treatments for osteoporosis exist, only a small
proportion of older individuals receive them, even after
major fracture.
An expert working group of the European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoar-
thritis (ESCEO) convened to discuss the current management
strategies for older patients in the context of pharmacological
and non-pharmacological interventions.
Ageing and age-related changes to the body
The average life expectancy of persons in the countries be-
longing to the Organisation for Economic Co-operation and
Development (OECD) is now 79.5 years [4]. Over the last
50 years, these countries have gained about 11 years in life
expectancy, with several (notably South Korea, China, Indo-
nesia and Turkey) gaining over 25 years. In Europe, mean life
expectancy at birth for women is 82.6 years (2009 figures) and
for men is 76.7 years [5]. In the USA, the segment of the
population over 85 years old comprises 5.7 million
persons at present (1.8 %) and is expected to rise to
14.1 million by 2040 [6].
As the world’s population ages, then the numbers of indi-
viduals who will face the problem of increased fracture risk
will increase inexorably. The 12 months cumulative mortality
following hip fracture is about 30 % [7, 8]. Mortality risk is
higher in men (about double) as compared to women [2, 7, 8]
and men appear more likely to suffer from markedly muscle
loss after hip fracture [9]. In addition to the strong sex-
difference in survival following an initial hip fracture, risk of
a second hip fracture is increased in the patients that do
survive and this carries with a strongly elevated 1-year mor-
tality risk [10]. Thus by proactively treating older individuals
who are at high risk of osteoporotic fracture, it might be
possible to improve markedly their long-term outcome. Those
who do survive have high probability of acquiring co-morbid
disease and disability; thus putting a strain on healthcare
systems and reducing the quality of life of the oldest old [11].
Another major problem in the older individuals is the
decline in muscle function. This is an age-dependent condi-
tion, but it is often exacerbated by reduced mobility (caused
for instance by osteoarthritis or obesity) and/or by poor nutri-
tion. Reduced muscle function or weakness is one component
of the frailty syndrome, which also includes unintended
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weight loss, self-reported exhaustion, slow walking speed and
low physical activity [12], as proposed by Fried and col-
leagues [12]. Greater evidence of a “frail phenotype” is asso-
ciated with a substantially higher risk of recurrent falls and
fractures and this risk is largely independent of age [13].
The SHARE frailty instrument, developed for the SHARE
study (Survey of Health, Ageing and Retirement in Europe), is
based on the criteria of Fried and colleagues has been validat-
ed and is predictive of all-cause mortality [14, 15]. An online
version is provided as a simple tool for practitioners to obtain
an indication of the frail and pre-frail status of individuals. In a
non-institutionalised population aged 50 years and older
(N=31,115) in the SHARE study, the percentage of frail
women was 7.3 % and of frail men was 3.1 % [16].
Osteoporosis in older individuals
A definition of osteoporosis
The operational definition of osteoporosis (endorsed by the
World Health Organization [WHO]) is a bone mineral density
(BMD) T-score of −2.5 or lower (i.e. at least 2.5 standard
deviations below average bone mineral density of healthy
young individuals), where BMD assessed by dual X-ray ab-
sorptiometry (DXA) at spine or hip. The same definition is
applied to men and women, with the same reference popula-
tion used for both (the NHANES III survey of women aged
20–29 years). It is clear however that the mechanisms of bone
loss differ between men and women [17–19].
During the diagnosis of osteoporosis it is, of course, im-
portant to determine if the patient has primary osteoporosis
(age-related bone loss) or secondary osteoporosis, caused by
underlying diseases, amenable to interventions, such as met-
abolic disease, nutritional deficiencies, or medication (partic-
ularly glucocorticoids). Secondary osteoporosis, especially in
older men, can be quite frequent [20]. For further information
concerning the diagnostic workup, the reader is directed to the
articles by Kanis and co-workers [21, 22].
The risk of fracture for an individual is therefore related to
BMD, but is also dependent on a number of factors and most
particularly age, with the result that T-score alone is not
sufficient in defining fracture probability and who should be
treated [23, 24].
Fracture risk and age
The risk of sustaining a major fragility fracture in-
creases progressively with age, irrespective of BMD T-
score (Fig. 1). The apparent decrease in risk seen in the
oldest old segment is due to the competing effect of
mortality (i.e. an integration of two hazards: fracture
risk and risk of death).
In the general population without apparent clinical risk
factors for osteoporosis (the grey filled area in Fig. 1), fracture
risk increases with age. From the age of about 75 years and
more, the fracture risk is higher than in women with a T-score
of −2.5 SD. This is because, after the age of 75 years, the
average T-score in the general population falls below −2.5 SD.
Thus, a T-score of −2.5 SD is protective since, on average,
women at this age have a lower T-score [23].
When prior fracture is integrated into the BMD-based risk
score model (the profiles with the thicker lines in Fig. 2), the
10-year risk estimate profiles according to age, more closely
match the epidemiological data (grey area).
The objective of the risk calculation is therefore to identify
the individuals at higher fracture risk, whether younger or
older, and to provide treatment accordingly. If it were decided
to treat everyone with a risk of over 5 %, then virtually the
whole population over the age of about 60–65 years would be
treated, whereas if the threshold was 20 %, a proportion of
predominantly older individuals would be treated. The pro-
portions of the population according to age who might be
treated according to different risk probabilities are illustrated
in Fig. 3 (in Japan for this example).
The intervention thresholds for osteoporosis depend on
regional treatment and reimbursement policies and these are
increasingly guided by economic evaluations to determine
cost-effective intervention thresholds [26]. Figure 4 shows
the proportion of the population aged between 50 and
89 years old that have a probability of 20 % or more
(darker portion of bars), or 10 % or more (total height
of bars) for major fracture. Some countries, such as
Romania and Bulgaria, have very low risk, whereas
others, such as Denmark, have much higher risk.
Of the various risk assessment tools developed in osteopo-
rosis, the FRAX® model, endorsed by the WHO, is the most
widely used. FRAX is designed to predict the probability over
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Fig. 1 Risk profiles for British women by age, according to BMD T-
score (calculated using FRAX). The grey area represents the risk in the
general female population having no apparent clinical risk factors for
osteoporosis
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10 years of a major (i.e. hip, spine, wrist or humerus) osteo-
porotic fracture [28]. It adjusts the result in very old patients
for the competing hazard of death—which is known to be a
source of inaccuracy in risk estimates for geriatric studies [29].
It has been updated since its first release, particularly by taking
into account glucocorticoid dose.
Diagnosis guidelines
Several clinical groups are involved in the diagnosis and
recommendations concerning the treatment of osteopo-
rosis. Two of these, the National Osteoporosis Founda-
tion (NOF) in the USA and the National Osteoporosis
Guideline Group (NOGG) in the UK, have recently
updated their guidelines and these provide an interesting
contrast in views with respect to their use of FRAX as
a tool for decisions on intervention (Table 1). Whereas
NOF suggests that a FRAX calculation is warranted
when the BMD indicates elevated fracture risk, the
decision to treat rests mainly on BMD; NOGG suggests
that FRAX should be used in a case-finding exercise
and the BMD should be performed in cases where the
risk estimate is in a borderline zone.
In cases where the diagnostic threshold is crossed
(i.e. elevated risk), additional clinical data might be
sought to determine whether treatment should be initi-
ated. This could be BMD (as suggested by NOGG), if
not already done. Biomarker analysis might also be of
potential interest, since high levels of bone turnover
markers are associated with increased fracture risk in
post-menopausal women [32].
One of the goals of this risk analysis exercise is to improve
the targeting of anti-osteoporosis medication to ensure that the
individuals who need to be treated are identified and presented
with their therapeutic options.
The guidance of NOF concerning the intervention thresh-
olds for treatment (whilst focusing on men and women
50 years and older) is to treat if T-score ≤ −2.5 at femoral
neck; or, if the T-score is between −1.0 and −2.5 and the 10-
year probability of fracture (on FRAX) is ≥ 3 % for hip or ≥
20 % for a major fragility fracture. The guidance of NOGG is
to treat when the age-related fracture probability exceeds the
intervention threshold given by FRAX (where the FRAX
threshold is the risk equivalent to a woman with a prior
fragility fracture). The age-dependent intervention thresh-
old favoured by NOGG is designed to avoid under-
prescription of treatment in eligible younger patients as
well as the over-prescription in older age groups that
could arise from a fixed threshold.
The FRAX defined intervention threshold therefore corre-
sponds to “severe osteoporosis”, i.e. the presence of at least
one fragility fracture [33]. Other definitions of severe osteo-
porosis or high-risk patients could include that used in the
GLOW study (Global Longitudinal Study of Osteoporosis in
Women) [34], of patients having an age ≥ 65 years and a prior
fracture or at least 2 other FRAX risk factors (parental
hip fracture, current smoker, less than or equal to three
alcoholic drinks/day, rheumatoid arthritis, current corti-
costeroid use, body mass index (BMI)<20 kg/m2, or
secondary osteoporosis).
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Fig. 3 The proportions of Japanese women by age, who should be
treated for osteoporosis, according to their 10-year risk estimate for major
fragility fracture (calculated using FRAX) (adapted fromKanis et al. [25])
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Fig. 2 Risk profiles for British women by age, according to either history
of prior fracture, or BMD T-score, or an integration of these two risk
factors (calculated using FRAX). a Major osteoporosis fracture risk. b
Hip fracture risk. The grey area represents the risk in the general female
population having no apparent clinical risk factors for osteoporosis
Costs
Given a rational strategy of patient identification, a pharma-
ceutical anti-osteoporosis treatment can change from being
cost-effective to being cost-saving in the oldest old [26].
Using a Markov cohort modelling analysis, Lippuner
and colleagues [35] estimated the costs associated with
the treatment of patients in Switzerland whose fracture
risk was estimated using 2 FRAX-based approaches,
with the willingness-to-pay threshold for one Quality-
adjusted Life-Year (QALY) was set at twice the gross
domestic product (GDP) per capita and a first-line treat-
ment with alendronate (original molecule). The analysis
found that treatment was cost-effective in women hav-
ing a 10-year risk for a major osteoporotic fracture of
13.8 % or more, whereas for men the risk estimate
should exceed 15 %. Using a translational approach,
i.e. the equivalence to a prevalent spine or hip fracture,
it was found that in individuals having a previous
fragility fracture, treatment was cost-effective in women
aged over 60 years and in men aged over 55 years, and
cost-saving above the age of 75 years.
Therapeutic approaches to osteoporosis: nutritional
supplementation and vitamin D
Vitamin D plays an essential role in the maintenance of bone
strength and muscle function. This nutrient/cofactor is in-
volved in the intestinal absorption of calcium and phosphorus,
for the mineralization of bone and maintenance of muscle
quality as well as a variety of beneficial effects on other organ
systems (see review by Boucher [36]).
Vitamin D is synthesised in skin during sun exposure as
well as ingested as part of a balanced diet. Older individuals
synthesise lower amounts of vitamin D in skin (they also tend
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Fig. 4 The proportions of
Europeans in each country who
should be treated for osteoporosis,
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probability estimate (FRAX) for
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Table 1 Intervention guidelines for osteoporosis, with a focus on older individuals
NOF NOGG
BMD testing Women aged ≥65 years If suggested by FRAX case-finding analysis
Men aged ≥70 years
Initiate therapy in those with T-scores ≤2.5
(at femoral neck, total hip or lumber spine)
Vertebral imaging Women aged ≥70 years Not mentioned
Men aged ≥80 years
FRAX Its use is warranted in patients with low femoral neck
BMD. Noted that using FRAX in patients with low
BMD at the lumbar spine with relatively normal
levels at the femoral neck leads to an underestimation
of fracture risk.
Case-finding using FRAX in all post-menopausal
women and men aged ≥50 years.
Initiate therapy following discussion of risk with patient
NOF National Osteoporosis Foundation (USA) [30]
NOGG National Osteoporosis Guideline Group (UK) [31]
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to expose their skin less than younger adults) and they fre-
quently have nutritionally impoverished diets. Thus many
older people suffer from hypovitaminosis D [36].
A large number of clinical studies have tested the effects of
vitamin D supplementation (often in combination with calci-
um) on fracture risk in older and/or osteoporotic population
samples; these have yielded surprisingly varied results and
even the meta-analyses have returned equivocal results. It may
be, as suggested recently [37], that many of these studies were
poorly designed from amethodological viewpoint, in that tests
of a causal relationship between a nutrient and a metabolic
endpoint (or fracture risk) are fundamentally fraught, because
the baseline status of the nutrient may vary widely between
individuals and the typical, sigmoid response functions seen
for nutrients are very steep.
In a pooled analysis of 11 trials (N=31,000) a lower frac-
ture risk was associated with patients having a plasma con-
centration of 25-hydroxy-vitamin D (25-OH-D) of at least
60 nmol/L at baseline as compared with those having levels
below 30 nmol/L [38]. In a recent analysis of a cohort from the
NHANES survey, both major osteoporotic fracture risk and
hip fracture risk were significantly related to serum 25-OH-D
levels within a period of up to 10 years follow-up. Interest-
ingly, the relationship was linear for major fractures and
quadratic for hip fracture, suggesting skeletal site specificities
and/or interactions with muscle strength or balance [39]. In-
deed there is growing evidence to suggest that vitamin D
supplementation has beneficial effects beyond a direct effect
on bone health. Bischoff-Ferrari [40] showed in a meta-
analysis that raising the levels of 25-OH-D decreased the
incidence of falls in older persons by 19 %. A possible
mechanism that underlies this effect is the beneficial influence
of vitamin D on muscle function, which in turn helps maintain
postural stability [41]. Other studies and meta-analyses on
vitamin D supplementation have concluded that it is associat-
ed with a reduction in all-cause mortality. Whilst several
studies and meta-analyses have shown a relatively robust
effect on reducing mortality, a recent meta-analysis [42], has
given a more muted endorsement. In the group of trials that
randomised participants to vitamin D with or without calcium
(n=35,116), the risk of death was reduced by 7 % (after
adjustment) during the 3 years of follow-up [42]. However,
the authors noted that the studies that investigated the effect of
vitamin D supplementation with calcium had lower mortality
rates than in the studies investigating vitamin D supplemen-
tation without calcium (4.4 vs 9.7 %, respectively in the
placebo/untreated participants). They found that risk of death
in older persons was reduced if vitamin D was given with
calcium (hazard ratio, 0.91; 95 % CI, 0.84–0.98) but not if
vitamin D alone. In a recent prospective study [43] in 5,292
older persons (85 % women) who were randomised to
daily vitamin D3 (800 IU), calcium (1,000 mg), both, or
placebo, and followed-up for 3 years, found however no
effect on mortality.
Most of the evidence therefore seems to support the bene-
ficial effects of daily vitamin D supplementation. Moreover, it
would appear that sufficient levels of vitamin D are a prereq-
uisite for the efficacy of osteoporosis medication [44]. The
recommendation of a dose of 800 IU/day (20 μg/day) in older
adults (>70 years) has been adopted bymost European bodies,
as well as the International Osteoporosis Foundation (IOF)
and the Institute of Medicine (IOM) and was also advised in a
recent ESCEO consensus paper [45–47].
The ESCEO guideline also provided some target thresh-
olds for plasma 25-OH-D levels (Table 2) and whilst most of
the background data which was evaluated to produce these
threshold was in women (andmostlymiddle-aged or older and
having osteoporosis), they are applicable in both men and
women. The NHANES cohort and the MrOS Sweden
study, evidenced in men the associations between serum
25-OH-D levels and fracture risk [39] or all-cause mor-
tality [48], respectively.
There is probably no strong necessity to measure circulat-
ing levels of 25-OH-D in older patients with suspected high
fracture risk and indeed the present cost of testing far exceeds
that of supplementation [36]. Vitamin D supplementation
should be started de facto, and this should precede any bis-
phosphonate therapy [44, 47].
Table 2 Threshold levels of 25-hydroxy-vitamin D in the serum and their impact on bone health
Serum 25-OH-D level Definition Impact on bone health
< 25 nmol/L (<10 ng/L) Vitamin D deficiency Mineralization defects
< 50 nmol/L (<20 ng/L) Vitamin D insufficiency Increased bone turnover and/or PTH
50–75 nmol/L (20–30 ng/L) Vitamin D sufficiency Neutral effect (bone turnover and PTH normalised),
desirable benefits on fracture, falls and mortality
> 75 nmol/L (>30 ng/L) Desirable target in the fragile individuals or oldest old
due to the optimal benefits on fracture, falls and mortality
125 nmol/L (50 ng/L) Upper limit of adequacy Possibility of adverse effects above this level
Adapted from Rizzoli et al. [47]
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Adverse effects with vitamin D supplementation
Vitamin D supplementation is safe, but caution is ad-
vised immediately after treatment initiation in case of
nausea, vomiting, gastrointestinal (GI) reflux or exces-
sive thirst, since these symptoms could indicate undiag-
nosed hyperparathyroidism or overdosage of vitamin D.
It should be noted that hyperparathyroidism becomes
more common with age, especially in women. The
adverse effects of hypercalcemia/hypercalciuria and
nephrolithiasis are more frequently associated with high
serum 25-OH-D levels (>125 nmol/L), which has been
set as the potential upper limit of adequacy [47].
Calcium supplementation
It is important to ensure the sufficient calcium intake through a
balanced diet. It appears that an intake of more than 1000 mg/
d is sufficient for bone health [49, 50]. A recent meta-analysis
[51] which concluded that calcium supplementation (without
coadministered vitamin D), might increase the risk of myo-
cardial infarction (MI) has provoked much debate in the
professional press. This study appears to present numerous
shortcomings that call into question is true validity [52], not
least the fact that most of the data come from bisphosphonate-
treated osteoporosis patients and a recent epidemiological
study of this patient profile has concluded that bisphosphonate
usage reduced MI risk [53].
Dietary protein intake
Nutritional insufficiency andmalnutrition are frequent in older
people [54] and both can result in deficits in essential nutri-
ents. Malnutrition and particularly the protein-energy malnu-
trition seen in many older people is a major risk factor for
sarcopenia and frailty [55, 56]. In a small prospective study of
hip fracture patients in Australia (72 % women), 58 % of
patients admitted to hospital were undernourished and 55 %
had a vitamin D deficiency [57]. Raynaud-Simon and col-
leagues [58] put the incidences of protein-energy malnutrition
as 4–10% of elderly persons living at home, 15–38% of those
in institutional care, and 30–70 % of hospitalized elderly
patients. Questionnaires such as the Mini Nutritional Assess-
ment (MNA) or the SNAQ65+, which have been validated in
older persons [59, 60] are useful in this respect to assess
nutritional status.
The importance of adequate nutrition for bone health may
be appreciated by studies that have assessed plasma levels of
insulin-like growth factor-I (IGF-I) in older patients. This
important trophic hormone, which mediates the effects
of growth hormone (GH), has growth-promoting effects
on almost every cell in the body and especially skeletal
muscle, cartilage and bone. It regulates phosphate
reabsorption in the kidney and has a stimulatory effect
on the active uptake of Ca2+ and phosphate (PO4
2−)
from the intestine via the renal synthesis of calcitriol.
Its production in the liver may be severely inhibited in
conditions of poor nutrition (see Fig. 5).
The plasma IGF-I concentration has utility as a nu-
tritional biomarker under a range of conditions and may
be taken into account in a nutritional assessment [61].
Protein supplementation can lead to a rapid normalisa-
tion of IGF-I levels in frail older adults and in recent
hip fracture patients (Fig. 6a, b respectively). The 2002
IOM guidelines recommended a protein intake of
0.80 g/kg body weight per day and the 2005 US guide-
lines maintain this RDA in persons aged over 70 years
[64]. Other clinical experts argue however that in view
of the impaired protein assimilation of older individuals,
the RDA should be increased to 1.0 or 1.2 g/kg per day
in this older age group [65–67].
Strategies to prevent falls in older individuals
The elderly are prone to falling [13]. Some of the risk
factors are modifiable and should be addressed where
possible. Patients who have recovered from a major
fracture are significantly more likely to fall, probably
because of the combination of muscle loss during the
GHProtein
intake
IGF-I Muscle
PO42-
Kidney Bone1,25-(OH)2D3
Ca2+
PlasmaPO42-
Intestine
Fig. 5 A schematic diagram showing the central role of IGF-I in bone
andmuscle health. The production of IGF-I in the liver and other tissues is
regulated by growth hormone (GH) secreted by the hypothalamus; this
production is also influenced by the nutritional status. IGF-I has trophic
effects on skeletal muscle and bone, and regulates phosphate reuptake in
the kidney proximal tubules. Via a stimulatory effect the kidney (along
with that of parathyroid hormone) IGF-1 raises the plasma level of the
calcitriol (1,25(OH)2D3) form of vitamin D, and so enhances the active
uptake of Ca2+ and phosphate (PO4
2−) from the intestine
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convalescent period and balance impairment [68]. In a
study of older women (65–75 years) with previous
fracture history, the balance was found to be inferior
to that of older women with no fracture and younger
women with a fracture history. Without corrective mea-
sures, this situation can persists for up to 10 years [69].
Other (intrinsic) risk factors include, gait deficits, dizzi-
ness and orthostasis, visual impairment, depression,
functional and cognitive impairment, low body mass
index, urinary incontinence, chronic musculoskeletal
pain, female sex, and being 80 years and older [70].
In men, a further association has been found between
increased risk of fracture and erectile dysfunction, pre-
sumably in relation to frailty or hypogonadism [71]. In
a prospective epidemiological study, older frail women
(according to the Fried frailty phenotype) had a signif-
icantly greater risk of recurrent fall than robust women
and in the age group of least 80 years, this risk was
almost doubled [72].
Although a number of risk factors for falling are not
modifiable, such as age and concomitant diseases that
respond poorly to treatment (e.g. neurological impair-
ments, neuromuscular and musculoskeletal diseases),
others are, to some extent, modifiable. Whatever the
medical history, individuals should be assessed for their
level of frailty. Frailty and low muscle strength are
associated with a higher risk of falling [73, 74]. Mod-
ifiable factors include correcting decreased visual acuity,
reducing or stopping medications that can diminish
awareness and/or balance, and encouraging modifica-
tions to the home environment (correcting slippery
floors and mats, improving lighting, fitting handrails in
bathroom etc.) [75]. The prescription of certain exercise
programs, such as those that focus on gait, co-ordination
and functional tasks, as well as strengthening exercises
seem to improve clinical balance outcomes in older
people [76]. Although various types of exercise training
have been assessed in clinical trials in elderly patients,
no consensus seems to be apparent as to the most
suitable method to be applied in the oldest old. In a
systematic review with meta-analysis of 44 studies, in-
cluding 28 with a patient population aged ≥75 years,
Sherrington and colleagues [77] pinpointed the salient
aspects of effective programs being balance training,
total exercise dose and the prescription of exercises
other than walking. Balance training such as Tai Chi
in a group setting or at home appeared to be particu-
larly effective [78], as does the practice of Jaques-
Dalcroze eurhythmics (a music-based multitask pro-
gram) [79]. The total exercise dose should preferably
be at least weekly over 6 months [77]. An explanation
for the greater efficacy of programs without a substan-
tial walking component maybe that the latter diverts too
much time from balance training [77]. Weight-bearing
activity does however have other health benefits even in
the oldest old [68, 80, 81]. Whilst a positive effect of
exercise on muscle strength, balance or gait etc. does not
automatically translate into a reduction of fracture incidence,
it would appear that these improvements do positively impact
the physical functioning domain of Quality of Life and are is
therefore of clinical benefit [82].
Concomitant medication to be avoided in older adults has
been addressed in the updated Beers criteria from the Amer-
ican Geriatrics Society [83]. It might be noted that antiepilep-
tic drug therapy is associated with lower BMD and increased
nontraumatic fracture risk [84].
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Therapeutic approaches to osteoporosis: pharmacological
strategies
Efficacy of osteoporosis drugs
The efficacy of the available pharmacological agents for the
treatment of osteoporosis in increasing bone strength and
reducing osteoporotic fracture risk is well established, al-
though this evidence is generally better for the prevention of
vertebral fractures than that for non-vertebral and hip frac-
tures. Figure 7 presents the efficacy results (forest plots:
estimates of treatment effect versus placebo, with the 95 %
confidence intervals) in post-menopausal osteoporosis (PMO)
for the major pivotal studies on the analyses of vertebral, non-
vertebral and hip fractures, respectively. For some of the
osteoporosis agents, the beneficial effect of treatment has also
been demonstrated on hip fractures (for strontium ranelate, hip
fracture analysis was post hoc).
Agents that have been approved for the treatment of oste-
oporosis in men include the bisphosphonates (alendronate,
risedronate and zoledronic acid), teriparatide denosumab,
and strontium ranelate (although the availability of the 2 latter
agents is more restricted geographically). Except for
zoledronic acid, which has been shown to reduce vertebral
fracture risk in osteoporotic men [98], the regulatory studies
for these agents were bridging studies that relied on changes in
BMD and biomarkers, to provide evidence that the changes
were essentially the same as observed in women.
The bulk of the evidence of efficacy rests on RCTs in post-
menopausal women between the ages of 50 and 80 years and
the evidence of anti-osteoporotic efficacy in the oldest old has
come primarily from subgroup analyses. A few major studies
did however specifically include older post-menopausal wom-
en and had prespecified analyses of fracture endpoints: the
HIP study on risedronate [90], a clodronate study [99], the
TROPOS and SOTI studies on strontium ranelate [97, 100],
the HORIZON study on zoledronic acid [101] and the FREE-
DOM study on denosumab [103] (Table 3). All of these
studies showed relatively convincing results on fracture end-
points after 3 years of treatment.
Additional evidence of efficacy in older populations has
been provided by the following references:
Alendronate
A post hoc analysis of the Fracture Intervention Trial
(FIT)-I of the patients aged ≥75 years, showed that there
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was a significant reduction in risk of new vertebral fracture
versus placebo of 38% [104]. Pooled data from the FIT trials
(I and II) with restrictive “documented” osteoporosis inclu-
sion criteria, were used to calculate age-specific fracture rates
by treatment group [105]. The relative risk reductions in new
fractures (spine, hip or wrist)—in favour of alendronate—
were fairly constant across the age groups (5-year intervals
from 55 to 85 years) for each site. Finally, in a small study in
women in long-term care (mean age 78 years, range 60–91;
T-score < −2 at lumbar spine or total hip; n=327), BMDwas
found to be increased at 2 years by alendronate versus
placebo with between-group differences of +4.4 % for spine
and +3.4 % at femoral neck [106].
Risedronate
A post hoc analysis of the pooled data from the pivotal
studies, Hip Intervention Program (HIP), Vertebral
Efficacy with Risedronate Therapy-Multinational
(VERT-MN), and VERT-North America (NA) (mean
age 83 years, range 80–98; T-score lower than −2.5, or
≥ 1 prevalent vertebral fracture; n=1,392), showed that
after 3 years follow-up, the incidence of new vertebral
fractures was 18.2 % in the risedronate group versus
24.6 % in the placebo group; an estimated reduction in
risk of 44 % [107].
Zoledronic acid
A post hoc subgroup analysis of the pooled data from
Health Outcome and Reduced Incidence with Zoledronic
Acid One Yearly (HORIZON) and the HORIZON Re-
current Fracture Trial (age≥75 years, T-score ≤ −2.5 at
femoral neck or ≥1 prevalent vertebral or hip fracture; n=
3,887) showed that at 3 years follow-up, the hazard ratio
for any clinical fracture (versus placebo) was 0.65; for
Table 3 Major studies that included significant numbers of older post-menopausal women and had analyses of fracture endpoints
Anti-osteoporosis Drug Study (reference) Main patient selection
criteria (number included)
Cumulative fracture
rate over 3 years of
treatment duration
Treatment effect
versus placebo
(p value)
Risedronate
HIP: 1st pop.a 70–79 yr BMD T-score −4 or
(−3 plus risk factor) (n=5,445)
Hip fracture: 1.9 vs 3.2 % RR: 0.6 (p=0.009)
HIP: 2nd pop.a ≥80 yr plus risk factor (n=3,886) Hip fracture: 4.2 vs 5.1 % RR: 0.8 (p=0.35)
Clodronateb ≥75 yr, but no proven osteoporosis
(n=5,579)
Hip fracture: 2.0 vs 2.1 % RR: 1.02 (n.s.)
Any clinical fracture: 9.5 vs 12.1 % RR: 0.80
Non-hip fracture: 5.2 vs 7.4 % RR: 0.71 (p=0.001)
Strontium ranelate
TROPOSc ≥74 yr BMD T-score −3.0 (n=1977) Hip fracture: 4.3 vs 6.4 % RR: 0.67 (p=0.046)
SOTI/TROPOSd ≥80 yr subgroup (SOTI inclusion criteria:
previous vertebral fracture) (n=1,488)
Vertebral fracture: 19.1 vs 26.5 % RR: 0.67 (p=0.013)
Non-vert fracture: 14.2 vs 19.7 % RR: 0.69 (p=0.011)
Hip fracture: 5.2 vs 7.4 % RR: 0.68 (p=0.12)
Zoledronic acid ≥75 yr, M/F,
with repaired hip fracture (n=2,127)
Vert fracture 1.1 vs 3.7 % RR: 0.34 (p=0.001)
HORIZON recurrent fracturee Non-vert fracture 9.9 vs 3.7 % RR: 0.73 (p=0.002)
Hip fracture: 2.0 vs 3.5 % RR: 0.70 (p=0.18)
Denosumab Vert fracture 3.1 vs 8.6 % RR: 0.36 (significant)
FREEDOMf,g ≥75 yr subgroup (n=2,471) Non-vert fracture 7.9 vs 9.0 % RR: 0.84 (n.s.)
Hip fracture 0.9 vs 2.3 % RR: 0.39 (p=0.01)
Teriparatide FPTh ≥75 yr subgroup (n=244) Vert fracture 5.2 vs 15.1 % RR: 0.35 (p<0.05)
Non-vert fracture 3.2 vs 4.2 % RR: 0.75 (p=0.66)
n.s. not significant, pop population, vert vertebral, vs versus, RR risk ratio; yr year
aMcClung et al. [90]
bMcCloskey et al. [99]
c Reginster et al. [97]
d Seeman et al. [100]
e Lyles et al. [101]
fMcClung et al. [103]
g Boonen et al. [102]
h Boonen et al. [109]
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any vertebral fracture was 0.34; and for non-vertebral
fracture was 0.73. All results were statistically significant
in favour of zoledronic acid [108].
Teriparatide
In a subgroup analysis of the Fracture Prevention Trial
(age ≥75 years in post-menopausal women with ≥ 1
moderate, or ≥ 2 mild, atraumatic vertebral fracture(s);
n=244; 1.9 years follow-up), treatment with teriparatide
(20 μg by daily self-injection) was associated with a 65%
risk reduction (versus placebo) for new vertebral fracture
and a 25 % reduction for new non-vertebral fragility
fractures. Teriparatide treatment was associated with a
9.2 % increase in lumbar spine and a 1.9 % increase at
the femoral neck BMD [109].
The onset of anti-fracture efficacy
Osteoporosis treatments are frequently found to be
under-prescribed, including in women who have
sustained an osteoporotic fracture. One reason for this
could be a reluctance of clinicians to prescribe treatment
because of doubts they might have over the effective-
ness of treatment in a short period of time [107].
However, as shown in Table 4, a number of RCTs have
demonstrated clinically significant benefits in terms of
fracture reduction within the first year of treatment.
Thus, even in an oldest old patient population, it would seem
that starting treatment with an anti-osteoporosis would, by and
large, have time to exert a beneficial effect on bone.
Safety of anti-osteoporotic drugs
In general, the safety margins of anti-osteoporotic
drugs are very good. Over the long-term, osteoporosis
treatments seem to maintain effectiveness and remain
safe [114]. The guidelines, erring on the side of pre-
caution, recommend treatment re-evaluation every 3–
5 years [30, 31]. For some patients, a “drug-holiday”
might be advocated [115]. The main issues concerning
drug therapy in the oldest old include reduced intesti-
nal absorption (thus lower bioavailability of oral treat-
ments), metabolism (slower metabolic rate), excretion
(impaired renal function), tissue sensitivity (skin ef-
fects), concomitant deficiencies (e.g., reduced endo-
crine responses to GH and PTH), and concomitant
treatments (invoking interactions for drug metabolism
as well as target organ effects).
The large RCTs and meta-analyses have shown that under
relatively stringent conditions, the adverse events tend to be
mild to moderate and reversible. The main adverse events and
their approximate incidences are presented in Table 5. As to
how these events distribute in the oldest old is less clear. A few
pharmacovigilance reports have associated some anti-
Table 4 The beneficial effect of an anti-osteoporotic treatment in older populations is generally seen after the first year of treatment
Type of vertebral fracture % risk reduction 1 year fracture rates (treated vs placebo) RR (95 % CI)
Alendronatea Symptomatic 59 n.a. 0.41 (n.a.)
Risedronateb Symptomatic 69 n.a. 0.31 (0.12–0.78)
Risedronatec Morphometric 81 2.5 vs 10.9 % 0.19 (0.09–0.40)
Zoledronic acidd Morphometric 60 1.5 vs 3.7 % 0.41 (n.a.)
Zoledronic acid (men)e Morphometric 68 0.9 vs 2.8 % 0.32 (0.12–0.88)
Clodronatef Morphometric 46 23.3 vs 12.7 % 0.54 (0.37–0.80)
Raloxifeneg Symptomatic 68 0.3 vs 0.8 % 0.32 (n.a.)
Strontium ranelateh Symptomatic 52 3.1 vs 6.4 % 0.48 (0.29–0.80)
Denosumabi Morphometric 61 0.8 vs 2.2 % 0.39 (n.a.)
n.a. not available
a [110]
b [111]
c [107]
d [92]
e [112]
f [99]
e [113]
g [96]
i [94]
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osteoporotic agents with rare but severe events (for in-depth
reviews see [116, 117]).
Gastrointestinal effects
The problems of upper GI events with oral bisphosphonates,
including irritation of the oesophagus, difficulty swallowing,
pain on swallowing and heartburn, are well known [118]. The
risk of upper GI events is lower when the drug intake instruc-
tions are properly followed (including an appropriate quantity
of water and post-dosing postural positioning) [119]. In
placebo-controlled trials, the reported rates of upper GI events
in the active and control arms are often very similar. For
example, in the FIT trial, such an event was reported by
47.5 % in the alendronate (10 mg/day) group and 46.2 % of
the placebo group [120]. In this trial and many others involv-
ing bisphosphonates, women with active ulcers or other GI
symptoms requiring daily treatment were excluded and it is
likely that the dosing instructions were well explained.
Patients with pre-existing upper GI disorders, such as
oesophageal stricture, achalasia, or poorly controlled
gastroesophageal reflux disease, should preferably, not
be treated with oral bisphosphonates.
Generic versions of bisphosphonates are associated with
higher rates of GI events and greater risk of treatment discon-
tinuation and this is probably mainly due to their faster disin-
tegration times [121]. Branded formulations allowing weekly
or monthly dosing are associated with lower rates of upper GI
effects than daily dosing for the same agent. Of potential
interest for the oldest old, is the development of an alendronate
formulation in a gel form that is easier to swallow [122].
Acute upper gastrointestinal bleeding (UGIB) may be a prob-
lem in older patients, but it is not clear that this is exacerbated by
bisphosphonates. In a Canadian population-based nested cohort
study [123] in patients aged ≥65 years (n=26,223), an incidence
rate of 0.4 % of acute UGIB within 120 days of treatment start
was found, with 60 % of cases being in patients aged over
80 years. Although relatively few of the affected older patients
had a past history of gastric ulcers, serious GI bleeding, or were
concurrent NSAID users, it was concluded that the rate was
concordant with the prevalence of UGIB (from any cause) in
the general population. Indeed, advanced age has consistently
been identified as a risk factor for UGIB and is likely related co-
morbidity and the use of multiple medications [123].
Diarrhoea and nausea is reported as common with stron-
tium ranelate; nausea, vomiting and gastroesophageal reflux
Table 5 Summary of adverse drug reactions by frequency according to class of anti-osteoporosis treatment
Very common ~1/10 Common ≥1/100 Uncommon <1/100
to ≥1/1,000
Rare and very rare
<1/1,000 and <1/10,000
Bisphosphonates -GI effects (oral
formulations)
–Musculoskeletal pain –Atrial fibrillation
–Acute-phase reactions
(IV formulations)
–Atypical fracture/delayed
fracture healing
–Osteonecrosis of the jaw
–Renal impairment
–Cutaneous hypersensitivity reactions
Denosumab –Infection –Cutaneous effects –Osteonecrosis of the jaw
–Rash –Cellulitis –Hypersensitivity reactions
–Pain in extremity
Raloxifene –Hot flushes –Leg cramps –Venous thrombo
embolism
–Stroke
–GI effects –Headache –Endometrial effects
–Flu syndrome –Rash
–Increased blood
pressure
–Mild breast symptoms
–Peripheral oedema
Strontium ranelate –Headache, nausea,
and diarrhoea
–Hypersensitivity reactions
–Venous thromboembolism
–Myocardial infarction
–Cutaneous effects
Teriparatide or
PTH (1–84)
–Limb pain –Headache, nausea, dizziness, vertigo –Myalgia, arthralgia –Renal failure
–Depression –Urinary incontinence,
polyuria, mephrolithiasis
–Allergic reactions
–Palpitations
–Sweating increased
–Dyspnoea, fatigue
References: Adapted from Rizzoli et al. [116] and the relevant Summaries of Product Characteristics (SmPCs)
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disease are common with teriparatide. For strontium ranelate,
these are very rarely severe and more frequently observed at
the beginning of treatment [97].
Vascular effects
The use of selective estrogen receptor modulators (SERMs),
such as raloxifene or basedoxifene, has been associated with
cutaneous flushing, particularly in the face and upper body
(‘hot flushes’), sweating and leg cramps [124, 125]. In the
pivotal regulatory study of raloxifene (MORE)—a PMO pop-
ulation aged 31–80 years (mean age 65 years; 36 month of
treatment), “hot flashes” (same as hot flushes) was the most
frequently reported non-serious adverse event (almost 10 %)
[85]. The incidence of these events appears to be lower in
women aged over 55 years, than in a younger age group [124].
The most well-known serious adverse drug reaction with
SERMs is venous thromboembolic events (VTE), including
deep vein thrombophlebitis and pulmonary embolism. In
MORE, the incidence rates of VTE were about 8–12/1,000
in the treated arms (RR vs placebo: 3.1) [85]. A meta-analysis
[126] has estimated a 62 % increase in risk of VTE with
raloxifene versus placebo. This effect of raloxifene is likely
due to the estrogenic effects of on the blood clotting system.
Higher risk of VTE has been observed with strontium ranelate
than in placebo, without clear explanation [127]. In an analy-
sis of the UK General Practice Research Database (GPRD)
database, Breart and colleagues [127] reported annualised
VTE rates of 7/1,000 for women (mean age 74 years) treated
with strontium ranelate, at a similar rate as in patients receiv-
ing alendronate. In that study and another large-scale
population-based cohort study [128], the underlying condition
itself (i.e., osteoporosis) appeared to be responsible for an
increased risk of VTE (possibly due to co-morbid conditions
such as previous fracture, or immobilization during hospital-
ization). In the Breart et al. study, the untreated osteoporotic
patients had a rate of VTE of 5.6/1,000 and an age-matched
non-osteoporotic cohort 3.2/1,000. In the Vestergaard et al.
study [128], the analysis showed an increased risk of VTE
with 3 different bisphosphonates compared to the general
population and only a borderline effect for raloxifene. It is
well established that the risk of VTE increases with age (along
with surgery and trauma) [129, 130]. The additional risk of an
anti-osteoporosis treatment, in terms of VTE, in the oldest old
is therefore very difficult to estimate.
Musculoskeletal pain
Chronic bone pain, as well as joint and muscle pain, have been
frequently associated with bisphosphonates, both oral and IV
(about 5–10 % of patients) and also to some extent with
raloxifene and teriparatide. Intravenous bisphosphonates are
associated with the highest rates with some severe cases
reported [131]. In 2008, the American Food and Drug Ad-
ministration (FDA) issued an alert on cases of severe pain
which can occur within days, months, or even years after
starting bisphosphonates [132]. When initiating once-weekly
dosage regimens of alendronate or risedronate, it has been
suggested that starting with lower daily dosages for about
2 weeks before switching to the more convenient, once-
weekly posology can avoid muscle pain [131].
Limb pain is a commonly reported adverse reaction with
teriparatide and, to a slightly lesser extent, back and joint pain.
In a placebo-controlled study in elderly women however
[109], the incidences of these events was not found greater
in the active arm as compared to placebo.
Immune reactions
The administration of intravenous bisphosphonates has been
associated with transient flu-like symptoms (myalgia, arthral-
gia, headache and fever), collectively called an acute-phase
reaction (APR). In a study with ibandronate, the incidence of
APR with the IV form was 4.9 versus 1.1 % for the oral form.
Higher rates of fever have been reported post-dosing with
zoledronic acid (around 30 %) [133]. The symptoms of
APR, which seem to be related by the release of pro-
inflammatory cytokines from circulating gamma-delta T cells,
generally appear 24–48 h after administration and resolve, for
some patients, within 48 h. The likelihood of having an APR
after an IV bisphosphonate, which is mostly observed after the
first administration, may be reduced by administration of
acetaminophen (paracetamol) prior to dosing.
Cutaneous hypersensitivity reactions are also reported with
several anti-osteoporosis drugs [134] although these remain
very rare. These events can be serious, with cases of Stevens-
Johnson syndrome and toxic epidermal necrolysis reported for
bisphosphonates; drug rash with eosinophilia and systemic
symptoms (DRESS) in patients receiving strontium ranelate
[134, 135]. They require prompt and permanent drug with-
drawal and treatment with corticosteroids. The prognosis is
good when treated rapidly.
Denosumab has been associated with higher rates of skin
infections and eczema [136]. Meta-analysis now indicates that
the increased risk is only borderline [136]. Denosumab is a
human monoclonal antibody that specifically binds and neu-
tralizes RANKL (receptor activator of nuclear factor-κB li-
gand), a signalling protein involved in osteoclast formation
and function, but is also expressed by activated T lympho-
cytes, B cells, and dendritic cells. In the FREEDOM trial, the
incidence of (serious) cellulitis (including erysipelas) was
significantly higher in the active arm (0.3 versus <0.1 %)
[94]. The increase rates of eczema and allergic skin reactions,
including dermatitis and rashes, seen in denosumab studies
are put down to “suboptimal tissue specificity” since RANKL
is also expressed in keratinocytes and Langerhans cells [136].
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The SmPC for teriparatide notes that this agent is rarely
associated with possible allergic events soon after injection,
but may include facial oedema, generalised urticarial and
acute dyspnoea.
Nervous system effects
Headache is commonly reported with strontium ranelate. The
event rate in the oldest old (>80 years) was 3.3 versus 1.7 %
on placebo. For teriparatide the rate of headaches in older
patients (>75 years) was 6 versus 5 % on placebo (lower than
in younger patients); the rate of dizziness was 9 versus 8 %
(the same as in younger patients) [109].
Rare cases of seizure have been reported in patients
treated with zoledronic acid and it has been hypothesised
that the transient hypocalcemia sometimes caused by this
bisphosphonate might alter the set point for seizure in-
duction [137].
Teriparatide treatment has been associated with headache,
vertigo and depression (SmPC).
Cancer
Rare cases of oesophageal cancer have been reported in patients
exposed to alendronate or other oral bisphosphonates, but the
results from epidemiological studies on prescription databases
have been conflicting. The FDA reports of oesophageal cancer
in patients who had received oral bisphosphonates, were after a
relatively short treatment times (median time to diagnosis of
2.1 years), thus minimising any probable causative effect. The
most recent analysis performed on the UK GPRD [138] con-
cluded that there was a small but significant increased risk of
oesophageal cancer in women. Of the 4,442 annually reported
cases of upper gastrointestinal cancer, 95 could be linked to
bisphosphonate use (Odds Ratio of 1.34 for bisphosphonates).
However, an analysis run by another group on the same data-
base concluded there was no significant association [139].
Raloxifene is associated with significantly lower rates of
breast cancer as compared to placebo or alendronate treated
patients [85, 140].
Teriparatide has been associated with osteosarcoma in ex-
perimental animals. However, there is no evidence of any
causal association between teriparatide treatment and osteo-
sarcoma in humans according to a long-term surveillance
study in the USA [141].
Cardiac effects
An increased risk of atrial fibrillation (AF) has been observed
in the pivotal HORIZON study with zoledronic acid. The
incidence of AF was 1.3 % in the active arm of zoledronate
trial in PMO, versus 0.5 % on placebo (p<0.001) [92]. Post
hoc analyses of other bisphosphonate trials and several large
population-based studies have, however, been inconsistent in
their findings, with no conclusive evidence that AF risk is
increased. Screening for AF in the older patient may be
however important since it is known that the prevalence of
AF increases with age, roughly doubling every decade, so that
in individuals aged over 85 years the rate is about 10 % [142].
The recent update of the notice for strontium ranelate notes
a signal of increased myocardial infarction incidence (1.7
versus 1.1 % in placebo) with a relative risk of 1.6.
No increase in risk of cardiovascular mortality with use of
bisphosphonates is reported and indeed a decrease in myocar-
dial infarction has been associated with bisphosphonate use in
patients with rheumatoid arthritis [53].
Impaired fracture healing and induced bone weakening
Regarding fracture healing, data from large clinical trials with
bisphosphonates indicate no evidence to support stopping
therapy whilst a fracture heals.
On the other hand, rare cases of osteonecrosis of the jaw
(ONJ) have been reported in recent years. These involve
exposed bone in the maxillofacial region that show negligible
healing of over a period of 8 weeks. They are mostly (about
95 %) reported in cancer patients receiving high-dose
IV bisphosphonates for the prevention or treatment of
cancer-related bone disease and in these cases treatment
should be stopped. No cases of ONJ have been pro-
spectively identified the major RCTs of bisphosphonates
(>60,000 patient-years of exposure) [143]. There have
been a few reports of denosumab-related ONJ in the
literature, but the incidence rates seem be similar to
those of zoledronic acid [136].
Case reports of atypical subtrochanteric, low-trauma, fe-
mur fractures in bisphosphonate-treated patients have been
published and some have noted prodromal thigh pain in the
preceding period. Although some epidemiological evidence
suggests there may be an association between these events
with duration of BP use, such atypical fractures can occasion-
ally be observed in untreated patients [144–146]. It remains a
duration of BP exposure beyond 5 years may constitute a risk
factor [147].
Renal safety
Renal insufficiency is common in older patients and therefore
causes concern for various drug treatments, including
bisphosphonates, because of their primary elimination via
the kidney [148]. Therefore, as a precautionary measure, these
products (both oral and IV forms) are not recommended in
patients with severe renal impairment (creatinine clearance
<30–35 mL/min). There have been rare reports of IV forms
being associated with nephrotoxicity, but these have been in
cancer patients with high treatment doses. Post hoc analyses
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of clinical trial data indicate however preserved anti-fracture
efficacy and are generally associated with stable serum creat-
inine levels, suggesting that there is no evidence to suggest
that the oral forms confer any increased risk in patients with
chronic kidney disease (stage 1, 2 or 3) [148].
Pain management
The management of chronic pain can be a challenge in older
patients in view of likely poly-medication, age-related meta-
bolic changes and declining function [149].
Chronic pain is often the result of fractured vertebrae
impinging on a nerve root. The use of surgical tech-
niques, such as vertebroplasty (an injection of a cement
into the vertebral body) or kyphoplasty (a similar pro-
cedure, but with the inflation a small balloon in the
bone cavity in an attempt to restore the original height
and form of the compressed vertebra), are still debated
in the oldest old [150].
Treatment with opioids can be of help, but a careful
selection should be made to minimise potential adverse
events (notably CNS and gastrointestinal effects) that
can be serious. Slow dose titration is advised and doses
should remain reduced as compared with younger
adults, with a longer time intervals between doses, and
regular creatinine clearance monitoring. Buprenorphine
shows a distinct benefit in improving neuropathic pain
symptoms and it has a half-life of drug activity that is
not increased in older patients or in those with renal
dysfunction [151].
Optimising therapeutic adherence in osteoporosis
Non-adherence with drug therapy in chronic asymptomatic
diseases is widespread [152] and this is also the case for
osteoporosis [153, 154]. Whilst different studies in osteopo-
rosis vary substantially in terms of methodology and patient
demographics [153], the results indicate yearly persistence
rates from 26 to 56 % for daily anti-osteoporosis regimens
and from 36 to 70 % for weekly regimens. Estimates of
compliance (MPR; see text box) ranged from 46 to 64 %
and 58 to 76 %, respectively, and thus also influenced by the
dosing interval. The epidemiological study by Rabenda
and colleagues [155] noted that the MPR at 12 months
was higher among patients receiving weekly as com-
pared to daily alendronate (70.5 versus 58.6 %;
p<0.001): similar results were found by Cramer et al
[153]. It has been noted that compliance tends to di-
minish with increasing follow-up duration and the drop
is particularly rapid over the first 2 years of treatment
[153]. In contrast, a recent post-marketing survey has
shown an excellent adherence to daily strontium ranelate
of 80 % at 1 year, 68 % at 2 years, and 64 % at
32 months [156].
Adherence, compliance and persistence: defining drug usage
The term adherence as used by WHO is “the extent to which a person’s
behaviour—taking medication, following a diet, and/or executing
lifestyle changes, corresponds with agreed recommendations from a
health care provider”; where it seems the word “agreed” is important.
The term compliance is sometimes used to describe more narrowly the
behaviour of patients in their respect of drug prescription dose and
interval of dosing; whilst the term persistence refers to the time from
initiation to discontinuation of therapy. Thus, WHO uses “adherence”
as a term that encompasses both compliance and persistence. Patients
may however be persistent without being particularly compliant, so
having the two terms is valuable.
In observational studies, compliance is usually defined as the medication
possession ratio (MPR), which is the number of days’ supply of
medication received divided by the period up to prescription refill.
Persistence is usually evaluated as the longest period of treatment
without a gap (or only a minimal gap) before prescription refill.
The clinical consequence of poor adherence is increased
risk of fracture. Siris and colleagues [157] observed that
overall fracture rate declined with improved MPR in women
aged ≥65 years (n=175,022): fracture rate was 5.1 % in
patients with MPR <50 % whereas it was 3.8 % in those with
MPR ≥80 %. In a meta-analysis of six studies (171,063
patients), Imaz and colleagues [158] estimated that the in-
crease in fracture risk for non-compliant patients (1–2.5 years
of follow-up) was 28 % for hip fractures and 43 % for clinical
vertebral fractures, and a further meta-analysis by Ross and
colleagues (0.8–4.2 years of follow-up; n=698,631) estimated
the increase in fracture risk for non-compliance at 30 % and
for non-adherence at 30–40 % [159].
Hiligsmann and colleagues, using a 3-year horizon (follow-
up) modelled optimal adherence and “real-world adherence”
[160]. In the real-world scenario, only 57 % of fractures were
prevented and the QALY gain was only 56 % of that expected
with full adherence. They concluded that an intervention
could be an efficient use of resources if it improved adherence
by 25 % and cost less than 100 euros per patient-year.
Adherence to prescribed medication regimens is difficult
for all patients and particularly challenging for the elderly.
They can be more forgetful, but this can be counteracted by
electronic and other reminders to prompt the patient or their
carer. However, it appears that about 70 % of non-adherence is
intentional, i.e. an active decision by the patient. Many patients
seem to perform an implicit risk/benefit analysis once given a
prescription for a new treatment and during their treatment,
which determines their subsequent behaviour [161–163]. Fur-
thermore, non-adherers are frequently “selectively non-
adherent”, i.e. whilst they might receive several different treat-
ments for different illnesses, they might be compliant for some
treatments, but not for others. As older patients are more likely
Osteoporos Int (2014) 25:2507–2529 2521
to have a number of co-morbid conditions, this selective non-
adherence is particularly apparent in this age group.
The reasons for not initiating treatment, and poor medica-
tion persistence, were assessed in a large cohort of US adults
[163]. The main reason underlying non-adherence was the
financial hardship of paying for the treatment (about 50 % of
respondents), followed by fear or experience of side-effects
(about 40 %), concerns about pharmacological treatments in
general (about 28%) and lack of perceived need for the treatment
(about 24 %); with other possible reasons playing more minor
roles (see Table 6). The lack of a perceived need for treatment in
many patients arises from the fact that they may not experience
any symptoms directly from their osteoporosis. Moreover, given
the rather wide range of side-effects outlined earlier, many
patients are likely to believe that the negative effects of anti-
osteoporosis medication outweigh any possible benefits.
In older individuals (without cognitive dysfunction), the
main medication difficulties, which give rise to non-
adherence, appear to centre around misunderstandings about
their disease and health in general, worries concerning adverse
effects and polypharmacy, and factors surrounding the patient-
provider relationship (and, in some cases, logistical barriers to
obtaining medications) [164].
The beliefs and misunderstandings about osteoporosis can
be quite varied. In patients with fragility fractures, it has been
reported that there may be failure to appreciate or even possi-
ble denial of the idea that their facture was related to bone
health. Such patients seem to reject the term “fragility” frac-
ture as not being strong enough to reflect their trauma [165]. In
addition, whilst patients may have a good understanding of
what osteoporosis is, they may not always understand how
their treatment can help [166].
The challenge is, therefore, to understand and anticipate
these motivations by identifying potential “non-adherers” in
the clinic. Predictors of medication non-adherence include
specific disease states, such as cardiovascular diseases and
depression [167]. A variety of interventions designed to im-
prove treatment compliance have been tested in the clinic,
which have been the subject of Cochrane reviews [168, 169]
and a further systematic review assessed osteoporosis medi-
cations in particular [170]. In general, the periodic follow-up
visits between patients and health professionals are beneficial,
but few intervention strategies were clearly efficacious. Pa-
tient coaching (e.g. a discussion with a nurse just before the
consultation that encourages the patient to ask questions), as
opposed to the distribution of written material, seems to
produce an increase in patient satisfaction with only a small
increase in consultation length. Since non-adherence is due to
a range of intentional (e.g. negative beliefs) and unintentional
(e.g. forgetting) factors, a simple “one size fits all” approach to
improving adherence is no longer tenable. Many current ad-
herence programs lack assessment and personalisation around
intentional and non-intentional adherence factors, which
limits their effectiveness.
During follow-up visits, patients should be questioned as to
their adherence, but not by using a closed-ended interrogative
approach. Instead, patients should be asked to describe how
they take their medicines in a non-threatening manner
avoiding any notion of judgment [167]. Assessment tools for
older adults may help for these interviews [171–173].
Conclusions on goals and challenges of osteoporosis
treatment in the oldest old
The risk of osteoporotic fractures in the geriatric (≥75 years)
and especially the oldest old (≥85 years) continues to be a
major healthcare concern. The impact of a major fracture on
patients’ lives is immense, often heralding the transition to
frailty and dependence. The costs borne by society are also
significant, both in terms of immediate care and rehabilitation
and over the longer term if dependence begins to take hold.
The fact that many older people—at high risk of fracture—
receive no treatment or highly inadequate treatment is unac-
ceptable. There is now sufficient evidence of the relatively
short-term benefits of treatment and of the long-term safety
profile of osteoporosis treatments. There is clear evidence that
many older people are under-nourished and vitamin D-
insufficient—a situation that needs to be rectified quickly
and before starting any pharmacological therapy. Because of
the widespread levels of poor adherence to treatment, this
needs to be addressed in order to ensure that the benefits of
treatment can be fully realized.
Whilst information on the relative efficacy of the available
osteoporosis treatment is lacking, analytical methods do per-
mit indirect comparison using data from published trials and
these are beginning to provide some perspective [174, 175]. In
the treatment of the oldest old, however, safety and dosing
considerations might possibly outweigh minor efficacy differ-
ences. In an interesting new development, it might be noted
that combined teriparatide and denosumab treatments in PMO
women (mean age 66 years) has shown particularly
Table 6 Predictors of non-adherence: overview of evidence
Factors that may affect medication taking behaviour Level of
evidence
Gender, income, age, race, personality Weak
Cognitive ability, depression, social support, self-
efficacy, health literacy, number of medicines, disease
seriousness beliefs, symptom experience, trust in HCP,
HCP-patient concordance.
Moderate
Concerns about treatment, beliefs about illness (cause,
timelines), cost of therapy, necessity (perceived need)
for treatment, perceived drug efficacy
Strong
HCP Healthcare provider (adapted from McHorney et al. [163])
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impressive results on hip and vertebral BMD after 3, 6 and
12 months of treatment [176].
An awareness of age-related osteoporosis risk, both among
healthcare professionals and potential patients, is making slow
progress and the laudable communication campaigns on Na-
tional and International levels have helped to make some
headway. In 2012, the IOF launched the Capture the Fracture
Campaign with the aim of reducing the incidence of second-
ary fractures by the creation of effective standard of care
procedures [177]. The idea is built around the adoption of
Fracture Liaison Services that provide comprehensive follow-
up of patients after an initial fragility fracture and it proposes
to establish a Best Practice Framework that will provide
regular updates [178], The year 2012 also saw the launch of
2Million2Many campaign by the US National Bone Health
Alliance (NBHA) which was designed to promote public and
professional awareness that 2 million bone breaks occur every
year in the USA [179]. The NBHA aims to reduce this number
by 20 % by the year 2020 and, to achieve this, it promotes the
implantation of the Fracture Liaison Services model of care
and provides online resources to healthcare professionals
[180]. It might also be noted that OsteoLink (a partnership
IOF and the Division of Bone Diseases at the Faculty of
Medicine, University of Geneva) is a program that is just
getting started, which sets up healthcare social networks to
support the osteoporosis community on a national basis [181].
Although none of these programs specifically targets the
oldest old, it may be hoped that they reach a wide audience
that will make intuitive associations.
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The golden rules of osteoporosis treatment
• Correct or prevent vitamin D insufficiency (≥800 IU/day)
• Ensure dietary calcium intake ~1000 mg/day
• Ensure adequate dietary protein intake ≥ 1 g/kg body wt/day
• Promote weight-bearing physical exercise
• Treat any disease that might be causing bone loss
• Reduce the risk of falls
• Reduce consequences of fall (hip protectors)
• Prescribe pharmaceutical treatment when indicated by risk assessment
• Provide adequate counselling and treatment explanation
• Follow-up patients with enquiries of persistence
• Re-evaluate therapeutic options after 3 years
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